drug · protein
LINZESS
updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Guanylyl cyclase C
all catalysts(0)
nothing on the calendar yet
Trials studying LINZESS
- phase2A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
- phase3A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
- phase3Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
- —Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
- phase3A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
- phase2A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
- phase3Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
News(1)
- Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to leadCSL has tapped a new leader to steer it through a make-or-break period. Ironwood's CEO since 2021 is hanging up his hat. CytoDyn's new helmsman is highlighting the company's "transformational perio…fiercebiotech · 28d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that